CleanSlate Centers

CleanSlate Centers is a SAMHSA-registered addiction-treatment facility located at Wilkes Barre, PA. The facility's programming is outpatient (Outpatient, MAT), not residential. Patient-level evaluation of this facility should distinguish three considerations: state licensure status, voluntary accreditation (CARF or Joint Commission), and clinical-framework alignment with current ASAM Criteria — each of which is independently verifiable.

Care levels at CleanSlate Centers

Level-of-care documentation: CleanSlate Centers is an outpatient-focused program (Outpatient, MAT) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. Under MHPAEA 2024 medical-necessity criteria disclosure, plan-specific criteria for each of these levels must be available to patients upon request. Mismatch between documented clinical need and offered level of care is a common source of authorization denial.

Insurance and payment

CleanSlate Centers accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. The facility also accepts TRICARE or military benefits. Benefit verification should be obtained in writing prior to admission and should document: network contract status for the specific insurance product, prior authorization requirements and approved day-count, applicable cost-sharing structure, and out-of-network secondary coverage (where applicable). Proceeding on verbal VOB creates material risk of post-admission benefit dispute.

Before you call

Pre-admission documentation for CleanSlate Centers should include ASAM-framework level-of-care justification, plan-specific Verification of Benefits with network-contract confirmation, written MAT policy for opioid use disorder patients where applicable, and licensure/accreditation verification. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.